Recursion Pharmaceuticals, Inc. Insider Trading

RXRX

Last 12 months

Insiders sold $7.6M and bought nothing on the open market.

All of the selling was scheduled in advance under 10b5-1 plans. No executive or director has bought shares on the open market in the last two years.

Net open-market

−$7.6M

0 buys · 35 sales

Under a 10b5-1 plan

100%

of the value sold

Insiders who bought / sold

0 / 6

executives and directors

Last open-market buy

None

in the last two years

Get an email when RXRX's executives or directors buy, or make a large sale outside a plan.

Trades · last 2 years

Date	Insider	Trade	Shares	Price	Value	Of their stake	Filing
Nov 3	Blake Borgeson Director	Sold10b5-1 plan	40,000	$3.88	155K	0.7%	Form 4
Oct 6	Blake Borgeson Director	Sold10b5-1 plan	50,000	$4.84	242K	0.8%	Form 4
Oct 6	Robert Hershberg Director	Sold10b5-1 plan	25,000	$5.00	125K	13%	Form 4
Sep 8	Najat Khan CEO and President	Sold10b5-1 plan	22,408	$3.52	79K	1.1%	Form 4
Sep 1	Blake Borgeson Director	Sold10b5-1 plan	30,000	$3.34	100K	0.5%	Form 4
Aug 4	Blake Borgeson Director	Sold10b5-1 plan	30,000	$3.25	98K	0.5%	Form 4
Jul 7	Blake Borgeson Director	Sold10b5-1 plan	40,000	$3.96	158K	0.6%	Form 4
Jun 18	Namandje Bumpus Director	Sold10b5-1 plan	3,963	$3.18	13K	3.0%	Form 4
Jun 5	Najat Khan CEO and President	Sold10b5-1 plan	23,588	$3.58	84K	1.1%	Form 4
Jun 5	Christopher Gibson Director	Sold10b5-1 plan	40,000	$3.62	145K	4.3%	Form 4
Jun 3	Namandje Bumpus Director	Sold10b5-1 plan	4,386	$3.54	16K	9.2%	Form 4
Jun 2	Blake Borgeson Director	Sold10b5-1 plan	30,000	$3.68	110K	0.5%	Form 4
May 22	Christopher Gibson Director	Sold10b5-1 plan	40,000	$3.08	123K	4.3%	Form 4
May 7	Christopher Gibson Director	Sold10b5-1 plan	40,000	$3.37	135K	4.2%	Form 4
May 5	Blake Borgeson Director	Sold10b5-1 plan	30,000	$3.52	106K	0.5%	Form 4
Apr 22	Christopher Gibson Director	Sold10b5-1 plan	40,000	$3.61	144K	4.2%	Form 4
Apr 7	Christopher Gibson Director	Sold10b5-1 plan	40,000	$3.10	124K	4.2%	Form 4
Apr 7	Blake Borgeson Director	Sold10b5-1 plan	30,000	$3.10	93K	0.5%	Form 4
Mar 23	Christopher Gibson Director	Sold10b5-1 plan	40,000	$3.25	130K	4.2%	Form 4
Mar 17	Ben R Taylor Chief Financial Officer	Sold10b5-1 plan	7,956	$3.39	27K	0.7%	Form 4
Mar 9	Najat Khan CEO and President	Sold10b5-1 plan	28,298	$3.35	95K	1.2%	Form 4
Mar 3	Blake Borgeson Director	Sold10b5-1 plan	170,000	$3.46	588K	2.6%	Form 4
Feb 19	Christopher Gibson Director	Sold10b5-1 plan	40,000	$3.46	138K	4.2%	Form 4
Feb 18	Ben R Taylor Chief Financial Officer	Sold10b5-1 plan	13,426	$3.08	41K	1.1%	Form 4
Feb 4	Christopher Gibson Director	Sold10b5-1 plan	40,000	$4.12	165K	4.1%	Form 4
Feb 3	Blake Borgeson Director	Sold10b5-1 plan	220,000	$4.20	924K	3.3%	Form 4
Jan 20	Christopher Gibson Director	Sold10b5-1 plan	40,000	$4.47	179K	4.2%	Form 4
Jan 6	Blake Borgeson Director	Sold10b5-1 plan	220,000	$4.36	959K	3.2%	Form 4
Jan 5	Christopher Gibson Director	Sold10b5-1 plan	40,000	$4.25	170K	4.2%	Form 4
Dec 29, 2025	Ben R Taylor Chief Financial Officer	Sold10b5-1 plan	21,383	$4.18	89K	2.7%	Form 4
Dec 22, 2025	Najat Khan Chief R&D Commercial Officer	Sold10b5-1 plan	124,403	$4.41	549K	17%	Form 4
Dec 19, 2025	Christopher Gibson Chief Executive Officer	Sold10b5-1 plan	40,000	$4.50	180K	4.2%	Form 4
Dec 4, 2025	Christopher Gibson Chief Executive Officer	Sold10b5-1 plan	40,000	$4.63	185K	4.2%	Form 4
Dec 2, 2025	Blake Borgeson Director	Sold10b5-1 plan	220,000	$4.37	961K	3.1%	Form 4
Nov 19, 2025	Christopher Gibson Chief Executive Officer	Sold10b5-1 plan	40,000	$4.16	166K	4.2%	Form 4
Nov 4, 2025	Christopher Gibson Chief Executive Officer	Sold10b5-1 plan	40,000	$5.21	208K	4.0%	Form 4
Oct 23, 2025	Christopher Gibson Chief Executive Officer	Sold10b5-1 plan	100,000	$5.70	570K	9.5%	Form 4
Oct 10, 2025	Christopher Gibson Chief Executive Officer	Sold10b5-1 plan	100,000	$6.04	604K	9.5%	Form 4
Sep 25, 2025	Christopher Gibson Chief Executive Officer	Sold10b5-1 plan	100,000	$4.76	476K	9.5%	Form 4
Sep 10, 2025	Christopher Gibson Chief Executive Officer	Sold10b5-1 plan	100,000	$4.71	471K	9.5%	Form 4

Nov 310b5-1 plan
Blake Borgeson
Director · sold 40,000 at $3.88
155K
0.7% of stake
Oct 610b5-1 plan
Blake Borgeson
Director · sold 50,000 at $4.84
242K
0.8% of stake
Oct 610b5-1 plan
Robert Hershberg
Director · sold 25,000 at $5.00
125K
13% of stake
Sep 810b5-1 plan
Najat Khan
CEO and President · sold 22,408 at $3.52
79K
1.1% of stake
Sep 110b5-1 plan
Blake Borgeson
Director · sold 30,000 at $3.34
100K
0.5% of stake
Aug 410b5-1 plan
Blake Borgeson
Director · sold 30,000 at $3.25
98K
0.5% of stake
Jul 710b5-1 plan
Blake Borgeson
Director · sold 40,000 at $3.96
158K
0.6% of stake
Jun 1810b5-1 plan
Namandje Bumpus
Director · sold 3,963 at $3.18
13K
3.0% of stake
Jun 510b5-1 plan
Najat Khan
CEO and President · sold 23,588 at $3.58
84K
1.1% of stake
Jun 510b5-1 plan
Christopher Gibson
Director · sold 40,000 at $3.62
145K
4.3% of stake
Jun 310b5-1 plan
Namandje Bumpus
Director · sold 4,386 at $3.54
16K
9.2% of stake
Jun 210b5-1 plan
Blake Borgeson
Director · sold 30,000 at $3.68
110K
0.5% of stake
May 2210b5-1 plan
Christopher Gibson
Director · sold 40,000 at $3.08
123K
4.3% of stake
May 710b5-1 plan
Christopher Gibson
Director · sold 40,000 at $3.37
135K
4.2% of stake
May 510b5-1 plan
Blake Borgeson
Director · sold 30,000 at $3.52
106K
0.5% of stake
Apr 2210b5-1 plan
Christopher Gibson
Director · sold 40,000 at $3.61
144K
4.2% of stake
Apr 710b5-1 plan
Christopher Gibson
Director · sold 40,000 at $3.10
124K
4.2% of stake
Apr 710b5-1 plan
Blake Borgeson
Director · sold 30,000 at $3.10
93K
0.5% of stake
Mar 2310b5-1 plan
Christopher Gibson
Director · sold 40,000 at $3.25
130K
4.2% of stake
Mar 1710b5-1 plan
Ben R Taylor
Chief Financial Officer · sold 7,956 at $3.39
27K
0.7% of stake
Mar 910b5-1 plan
Najat Khan
CEO and President · sold 28,298 at $3.35
95K
1.2% of stake
Mar 310b5-1 plan
Blake Borgeson
Director · sold 170,000 at $3.46
588K
2.6% of stake
Feb 1910b5-1 plan
Christopher Gibson
Director · sold 40,000 at $3.46
138K
4.2% of stake
Feb 1810b5-1 plan
Ben R Taylor
Chief Financial Officer · sold 13,426 at $3.08
41K
1.1% of stake
Feb 410b5-1 plan
Christopher Gibson
Director · sold 40,000 at $4.12
165K
4.1% of stake
Feb 310b5-1 plan
Blake Borgeson
Director · sold 220,000 at $4.20
924K
3.3% of stake
Jan 2010b5-1 plan
Christopher Gibson
Director · sold 40,000 at $4.47
179K
4.2% of stake
Jan 610b5-1 plan
Blake Borgeson
Director · sold 220,000 at $4.36
959K
3.2% of stake
Jan 510b5-1 plan
Christopher Gibson
Director · sold 40,000 at $4.25
170K
4.2% of stake
Dec 29, 202510b5-1 plan
Ben R Taylor
Chief Financial Officer · sold 21,383 at $4.18
89K
2.7% of stake
Dec 22, 202510b5-1 plan
Najat Khan
Chief R&D Commercial Officer · sold 124,403 at $4.41
549K
17% of stake
Dec 19, 202510b5-1 plan
Christopher Gibson
Chief Executive Officer · sold 40,000 at $4.50
180K
4.2% of stake
Dec 4, 202510b5-1 plan
Christopher Gibson
Chief Executive Officer · sold 40,000 at $4.63
185K
4.2% of stake
Dec 2, 202510b5-1 plan
Blake Borgeson
Director · sold 220,000 at $4.37
961K
3.1% of stake
Nov 19, 202510b5-1 plan
Christopher Gibson
Chief Executive Officer · sold 40,000 at $4.16
166K
4.2% of stake
Nov 4, 202510b5-1 plan
Christopher Gibson
Chief Executive Officer · sold 40,000 at $5.21
208K
4.0% of stake
Oct 23, 202510b5-1 plan
Christopher Gibson
Chief Executive Officer · sold 100,000 at $5.70
570K
9.5% of stake
Oct 10, 202510b5-1 plan
Christopher Gibson
Chief Executive Officer · sold 100,000 at $6.04
604K
9.5% of stake
Sep 25, 202510b5-1 plan
Christopher Gibson
Chief Executive Officer · sold 100,000 at $4.76
476K
9.5% of stake
Sep 10, 202510b5-1 plan
Christopher Gibson
Chief Executive Officer · sold 100,000 at $4.71
471K
9.5% of stake

How to read this. Insiders sell for many reasons: taxes, diversifying, a house. Open-market buys are rarer and say more. A 10b5-1 plan is a trading schedule set up months in advance, so those sales were not timed on news. Large holders (funds and 10% owners) are listed under Everything but not counted as insiders. If you own or watch RXRX, we send a push when an executive buys or makes a large sale outside a plan.

Source: SEC Form 4 filings, filed within two business days of each trade and checked for new ones every hour.

Peers

Biological Products, (No Diagnostic Substances) · Pick stocks to compare with RXRX

CompareIntrinsic value

CGENCompugen Ltd.

$2.03+1.00%75

CSBRChampions Oncology, Inc.

$4.83+0.00%26

FENCFennec Pharmaceuticals Inc.

$10.35-3.27%40

IVVDInvivyd Inc.

$0.63+8.93%10

PLXProtalix Biotherapeutics Inc.

$2.69+3.07%68

CHRSCoherus Biosciences Inc.

$0.85+5.46%10

EDITEditas Medicine Inc.

$2.73+5.00%40

STROSutro Biopharma, Inc.

$9.94+4.52%10

Held by ETFs

RXRX is in 53 US ETFs. The largest of them, with RXRX's weight in each:

Spot a number that looks wrong? Check it in RXRX's SEC filings or

Download this analysis as a PDF (Pro)

Data sourced from SEC EDGAR filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.

2 of 2 free stocks used today

Keep analysing RXRX

Create a free account and get 14 days of Premium: every stock and every tool.

Unlimited stocksQuality, fair value and dividends for 10,000+ stocks
Stock screenerFilter on quality, valuation and dividend safety
Portfolio trackerReal return, dividend calendar and portfolio quality
Editable DCFChange the assumptions and watch fair value move
Compare side by sideUp to 10 stocks in one table
Unlimited alertsPrice, P/E, Quality Score and yield

No card. Moves to Free after, unless you upgrade.

Already have an account?

Or come back tomorrow. Stocks on your watchlist are always free to view.